Drug Trial Radar · NCT06694935
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
Last checked: Nov 20, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Jan 6, 2025
Primary completion
Jul 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- 1Globe Health InstituteIndustry
- Sponsor type
- Industry
- First posted
- Nov 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose. In addition, the preliminary effects of QX1206 on antidiabetic activity and other metabolic parameters will also be evaluated.
Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions
QX1206Drug
QX1206 will be administered orally before bedtime
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 Dose (RP2D)Time frame: Baseline Day 1 up to Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centricity Research Toronto LMC.
Toronto, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.